PhaseII study of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion

PhaseII study of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion - PhaseII study of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016056

Enrollment

Registered

2014-12-26

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant pleural mesothelioma

Interventions

Pleurectomy/Decortication and Intraoperative Intrapleural Hyperthermic Cisplatin Perfusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: histologically proven MPM, surgically resectable (T1-3N0-2), without distant metastasis, and patients who are not candidates for EPP as a result of insufficient cardiopulmonary reserve, advanced age, or poor performance status (PS).

Exclusion criteria

Exclusion criteria: past history of malignant mesothelioma severe complication of heart, liver or renal function interstitial pneumonia possibility of pregnancy,patient with pregnancy past history of severe drug allergy concomitant cancer of other organs

Design outcomes

Primary

Measure	Time frame
disease free survival	—

Secondary

Measure	Time frame
overall survival side effect	—

Countries

Japan

Contacts

Public ContactHironori Ishibashi

Tokyo Medical and Dental University Thoracic Surgery

hishiba.thsr@tmd.ac.jp03-3813-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026